A Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial

NCT ID: NCT07119489

Last Updated: 2025-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-28

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to learn more about how Dialectical Behavior Therapy - Skills Training can help patients with cancer who smoke cigarettes cut down on or stop their smoking.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a study that aims to evaluate recruitment rates, feasibility, acceptability, and fidelity of Dialectical Behavior Therapy - Skills Training (DBT-ST) brief intervention.

Study population will include participants who smoke and are undergoing treatment with curative intent for their cancer or are in remission.

The study will include eight 60 minute sessions of DBT-ST and measurements of psychological states and smoking habits by interventionists. At follow-up participants will complete a survey on their intervention experience and ongoing use of DBT-ST. Interventionists will also complete a survey following each session to record time and materials use for future cost-effectiveness analysis.

At follow-up, participants and interventionists will engage in a one-hour qualitative interview with a study team member.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with cancer who smoke

Participants who smoke and are undergoing treatment with a curative intent for cancer or are in remission from cancer

Group Type EXPERIMENTAL

Dialectical Behavior Therapy -Skill Training brief intervention

Intervention Type BEHAVIORAL

A behavioral counseling approach for enhancing skills in emotion regulation, distress tolerance, and mindfulness

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dialectical Behavior Therapy -Skill Training brief intervention

A behavioral counseling approach for enhancing skills in emotion regulation, distress tolerance, and mindfulness

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Smoke ≥1 cigarettes every day in the past 30 days per participant report.
2. Smoked at least 100 cigarettes (5 packs) in lifetime.
3. Confirmation of cancer and are in active treatment with curative intent or in remission per enrolling investigator or electronic medical record.
4. Age ≥ 18 years at the time of consent.
5. Ability to understand and willingness to sign an IRB-approved informed consent, in English, directly.
6. Able and willing to participate in video conference.

Exclusion Criteria

1. Patients actively receiving external tobacco use counseling or using tobacco cessation medications.
2. Prior experience with more than five sessions of DBT-ST.
3. Life expectancy of six months or less.
4. Medical or psychiatric conditions limiting compliance with study requirements including suspected or reported cognitive impairment.
5. Self-reported use of any psychoactive substance \[except marijuana and nicotine\] within the last 30 days.
6. Have active and severe suicidal ideation at time of eligibility assessment or suicide attempt within the past month.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Atrium Health Wake Forest Baptist

OTHER

Sponsor Role collaborator

Wake Forest University Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marcia McCall, PhD

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Health Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Atrium Health Levine Cancer

Charlotte, North Carolina, United States

Site Status RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

James Morgan

Role: CONTACT

336-712-4491

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Boris Kiselev, MD

Role: primary

704-355-2000

James Morgan

Role: primary

336-712-4491

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ONC-CCS-2408

Identifier Type: OTHER

Identifier Source: secondary_id

IRB00131890

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.